Alex Arfaei

Large-cap pharma stocks have had a decent 2018, with strong earnings momentum primarily responsible for the optimism in the space. Tax cuts enabled companies to augment cash reserves, giving them flexibility to pursue inorganic growth to enrich product pipelines. Here's how large...

Pfizer Inc. (NYSE: PFE) reported mixed third-quarter results Tuesday that triggered a downgrade by BMO Capital Markets. The Analyst Analyst Alex Arfaei downgraded Pfizer from Outperform to Market Perform and lowered the price target from $47 to $46. The Thesis Pfizer's changed...

Bristol-Myers Squibb Co (NYSE: BMY) is down 24 percent from its year-to-date peak, and one Street expert said the price is just right. The Rating BMO Capital Markets analyst Alex Arfaei upgraded Bristol-Myers from Underperform to Market Perform and maintained a $47 price target. The Thesis...

The bearish case for Eli Lilly And Co (NYSE: LLY)'s stock is based on multiple concerns, but the stock's decline since the beginning of the year implies a better risk-to-reward profile, according to BMO Capital Markets.  The Analyst BMO's Alex Arfaei upgraded Eli Lilly from...

Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) both release their second quarter earnings reports this week. According to BMO Capital, investors should be buying Merck and selling Bristol-Myers ahead of earnings. Despite Merck being on the verge of...

Citing upcoming risks and not enough upside, BMO Capital Markets analyst Alex Arfaei has downgraded Zoetis Inc (NYSE: ZTS) to Market Perform. “Although we expect a good 2Q17, we doubt it will meaningfully change the company's long-term growth prospects. With consensus estimates rising to...

BMO Capital Markets earlier this week downgraded shares of Bristol-Myers Squibb Co (NYSE: BMY), citing strong near-term headwinds and the lower odds of a takeout. Near-Term Headwinds Analyst Alex Arfaei listed a few near-term evens he believes will likely further increase uncertainty about...

Merck & Co., Inc. (NYSE: MRK) traders that haven't already done so should mark May 10 on their calendars. The company announced in early January the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab)....

Investors appear to be pleased with Eli Lilly and Co (NYSE: LLY)'s business after the company updated the investment community with short- and longer-term guidance. Eli Lilly's stock gained more than 5 percent on Thursday and was trading higher by another 1.50 percent at $72.45 ahead of Friday's...

Pharmaceutical investors could breathe a sigh of relief after Donald Trump won the race to the White House, at least according to Alex Arfaei of BMO Capital Markets. Arfaei commented in a research report on Wednesday that a Trump presidency, coupled with a Republican Congress and the apparent...

On Friday, BMO Capital Markets analyst Alex Arfaei upgraded shares of Merck & Co., Inc. (NYSE: MRK) from Market Perform to Outperform, boosting his price target by $10, to $72. Bristol said that its CheckMate-026 study in first-line NSCLC had not managed to meet its primary PFS endpoint, and...

Despite topping the Street view, BMO said the second-quarter results of Merck & Co., Inc. (NYSE: MRK) is not "good enough" to change its Market Perform rating on the stock. Merck's quarterly revenue was about 1 percent above consensus and 1.5 percent above BMO's forecast, while EPS of $0.93 was...

BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...

BMO Capital Markets analyst Alex Arfaei is more concerned about AbbVie Inc. (NASDAQ: ABBV) due to increased uncertainty about big growth drivers. In the absence of it, the analyst downgraded the stock to Market Perform from Outperform and reduced the price target to $66 from $70. The analyst...